Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Buprenorphine (transdermal)

Opioid analgesic – partial μ-opioid receptor agonist

ATC code: N02AE01

Brand names: Transtec, Norspan, Butrans, BuTrans

Updated · Methodology

Indications

B

Moderate-to-severe chronic pain

Second line

Used in moderate-to-severe chronic pain with limited response to non-opioid agents. NG193 (2021) and 2018 do not place opioids as first-line for chronic non-cancer pain; they are considered only when alternatives fail. Starting dose: Transtec 35 mcg/h (patch changed every 96 hours); Norspan 5 mcg/h (weekly patch). Preferred in older patients and renal impairment due to lower accumulation. Long-term use with scheduled reassessment every 3 months and attempted gradual dose reduction.

Not for acute pain or opioid dependence – separate formulations are used.

Sources

  1. AEMPS: Ficha técnica de Buprenorfina (transdérmica) (2024)

ICD-10: R52.2 · ICD-11: MG30

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Chronic fatigue

Not recommended

Transdermal buprenorphine is an opioid analgesic, a partial μ-receptor agonist in patch form. It is prescribed for moderate-to-severe chronic pain when other drugs are ineffective (AEMPS Ficha Técnica). For chronic fatigue without a confirmed pain syndrome, buprenorphine is strictly not indicated. The drug has serious risks: opioid dependence ( boxed warning), respiratory depression, constipation, nausea, QT prolongation, fall and fracture risk in older adults, and withdrawal syndrome on abrupt discontinuation. If a buprenorphine patch was prescribed for fatigue, seek a second opinion immediately.

Sources

  1. AEMPS: Ficha técnica de Buprenorfina (transdérmica) (2024)
  2. NICE: Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206) (2021)

ICD-10: R53 · ICD-11: MG22

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

A semisynthetic opioid, partial μ-opioid agonist and κ-opioid antagonist. Higher μ-receptor affinity than morphine, producing long action and blockade of full agonists (morphine, fentanyl). Ceiling effect on respiratory depression – fatal respiratory depression risk is lower than with full agonists. Transdermal delivery gives steady levels over 72–96 hours (7 days for Norspan/Butrans). Half-life after patch removal 25–36 hours.

Safety

Boxed warning

FDA boxed warning: risk of addiction, abuse, severe respiratory depression, and death. Combination with benzodiazepines, alcohol, gabapentin, or pregabalin is hazardous. Prescribe only for clear indications, at minimum effective dose, and with scheduled review.

Contraindications

  • Buprenorphine hypersensitivity
  • Severe respiratory failure, acute bronchospasm
  • Severe hepatic impairment
  • Acute alcohol intoxication, delirium
  • Opioid dependence requiring full agonists
  • Brain tumors, raised intracranial pressure
  • Paralytic ileus
  • Concurrent MAO inhibitors or within 14 days of stopping them
  • Age under 18

Serious adverse effects

  • Respiratory depression (especially with benzodiazepines, alcohol, gabapentinoids)
  • Hypotension and bradycardia
  • Serotonin syndrome with SSRIs/SNRIs
  • Adrenal insufficiency with long-term use
  • Physical dependence and withdrawal
  • QT prolongation

Common adverse effects

  • Drowsiness
  • Nausea, vomiting
  • Constipation
  • Dizziness
  • Itching and erythema at patch site
  • Dry mouth
  • Headache

Pregnancy: can you take Buprenorphine (transdermal)?

Use in pregnancy carries neonatal abstinence syndrome risk when used in T3. For chronic pain in pregnancy, non-opioid measures are first-line; when an opioid is needed, short-term lowest-effective dose is preferred.

Breastfeeding: can you take Buprenorphine (transdermal)?

Buprenorphine passes into milk in small amounts. Compatible with breastfeeding with monitoring of infant sedation, weight gain, and feeding behavior.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Apply the patch to dry, clean, intact, hairless skin on the upper torso or upper arm. Rotate sites and avoid the same area for at least 3 weeks. Peak concentration is reached 60–80 hours after the first patch – an additional short-acting opioid may be needed during that window. Heating the patch site (hot shower, heating pad, fever) increases buprenorphine release – overdose risk. Do not cut the patch or use a damaged one. Avoid combining with other opioid analgesics without medical advice.

Common myths

Myth: «a patch is weaker than oral opioids.» Fact: buprenorphine at equivalent doses matches morphine, oxycodone, and fentanyl on analgesia; the formal ceiling on respiratory depression does not equal safety. Combined with alcohol, benzodiazepines, or gabapentinoids, the risk of fatal respiratory depression remains high. Myth: «no dependence with a patch.» Fact: physical dependence and withdrawal develop with prolonged use as with other opioids; taper gradually. Psychological dependence is less common.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Buprenorphine (transdermal) used for?

Buprenorphine (transdermal) is evaluated for the following indications with varying evidence strength: Moderate-to-severe chronic pain (evidence tier B), Chronic fatigue (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Buprenorphine (transdermal)?

Common side effects of Buprenorphine (transdermal) (≥ 1 in 100): Drowsiness, Nausea, vomiting, Constipation, Dizziness, Itching and erythema at patch site, Dry mouth. See the Safety section for uncommon and serious reactions.

Is Buprenorphine (transdermal) safe during pregnancy?

Use in pregnancy carries neonatal abstinence syndrome risk when used in T3. For chronic pain in pregnancy, non-opioid measures are first-line; when an opioid is needed, short-term lowest-effective dose is preferred.

Is Buprenorphine (transdermal) compatible with breastfeeding?

Buprenorphine passes into milk in small amounts. Compatible with breastfeeding with monitoring of infant sedation, weight gain, and feeding behavior.

Can you drink alcohol while taking Buprenorphine (transdermal)?

Combined with alcohol, benzodiazepines, or gabapentinoids, the risk of fatal respiratory depression remains high.

Who should not take Buprenorphine (transdermal)?

Buprenorphine (transdermal) is contraindicated in: Buprenorphine hypersensitivity; Severe respiratory failure, acute bronchospasm; Severe hepatic impairment; Acute alcohol intoxication, delirium; Opioid dependence requiring full agonists. Full list in the Safety section.

Does Buprenorphine (transdermal) carry an FDA boxed warning?

FDA boxed warning: risk of addiction, abuse, severe respiratory depression, and death. Combination with benzodiazepines, alcohol, gabapentin, or pregabalin is hazardous. Prescribe only for clear indications, at minimum effective dose, and with scheduled review.

Other drugs in this group

Dihydroergotamine, Eletriptan, Ergotamine, Fentanyl, Morphine, Paracetamol, Tapentadol, Frovatriptan